On May 16, 2024, the U.S. Food and Drug Administration (FDA) granted Imdelltra (tarlatamab-dlle) accelerated approval for people with extensive stage small cell lung cancer (ES-SCLC) following progression on or after platinum-based chemotherapy.
The approval is based on results from the DeLLphi-301 trial (NCT05060016). Participants with relapsed or progressive ES-SCLC after receiving platinum-based chemotherapy were given Imdelltra (tarlatamab-dlle) as follow-up therapy. Results showed that people receiving Imdelltra (tarlatamab-dlle) generally experienced some benefit from receiving therapy. Participants also saw the effects of those benefits for a meaningful period of time over several months. People who receive this drug should closely monitor side effects with their healthcare team, as some study participants experienced serious side effects.
Imdelltra (tarlatamab-dlle) is a new type of treatment for ES-SCLC known as a bi-specific T-cell engager. This type of therapy helps a person’s immune system identify and attack cancer cells in the body by binding to targets on both T-cells (a type of immune cell in the body) and the cancer itself. Imdelltra (tarlatamab-dlle) targets a protein on the surface of T-cells known as CD3 and a protein found on the surface of cancer cells known as DLL3, which is found in over 85% of people with SCLC. This exciting approval offers an entirely new type of treatment—and hope—for people living with ES-SCLC.
I went into clinical and let them do the non fda approved drug on the condition if it did not work I would get the fda, and all was agreed to know they tell me they can’t get it before all this I could walk and go to the bathroom, now I can’t to either is there anyway I can get this without clinical
Hello Bridget,
I’m sorry to hear about the trouble you’re having on your current treatment. Someone from GO2 will be reaching out to help, but you can also call our Helpline at 1-800-298-2436 or email support@go2.org so we can provide support.
Need help